Redmile reports 5.2% Immunome ownership stake
Immunome, Inc. reported that investment adviser Redmile Group, LLC and its principal Jeremy C. Green beneficially own 5,718,385 shares of Immunome common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Immunome, Inc. reported that investment adviser Redmile Group, LLC and its principal Jeremy C. Green beneficially own 5,718,385 shares of Immunome common stock. This stake represents 5.2% of the outstanding common shares.
The shares are held by private investment funds managed by Redmile, with Redmile and Green having shared voting and shared dispositive power over all 5,718,385 shares and no sole voting or dispositive power. The percentage is calculated using 91,710,277 shares outstanding as of November 3, 2025, plus 18,625,000 shares issued and sold as of December 18, 2025.
Redmile and Green state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunome. They each disclaim beneficial ownership beyond any pecuniary interest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Immunome (IMNM) does Redmile Group report?
How did Redmile Group calculate its 5.2% ownership in Immunome (IMNM)?
Does Redmile Group intend to influence control of Immunome (IMNM) with this stake?
Do Redmile Group and Jeremy C. Green fully accept beneficial ownership of their Immunome (IMNM) shares?
AI-generated analysis. How Rhea-AI works. Not financial advice.